PRODUCTID,PRODUCTNDC,PRODUCTTYPENAME,PROPRIETARYNAME,PROPRIETARYNAMESUFFIX,NONPROPRIETARYNAME,DOSAGEFORMNAME,ROUTENAME,STARTMARKETINGDATE,ENDMARKETINGDATE,MARKETINGCATEGORYNAME,APPLICATIONNUMBER,LABELERNAME,SUBSTANCENAME,ACTIVE_NUMERATOR_STRENGTH,ACTIVE_INGRED_UNIT,PHARM_CLASSES,DEASCHEDULE,NDC_EXCLUDE_FLAG,LISTING_RECORD_CERTIFIED_THROUGH
0002-0152_1761b768-7da0-44a9-bded-54c3bc63414a,0002-0152,HUMAN PRESCRIPTION DRUG,Zepbound,,tirzepatide,"INJECTION, SOLUTION",SUBCUTANEOUS,20231108,,NDA,NDA217806,Eli Lilly and Company,TIRZEPATIDE,2.5,mg/.5mL,"G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",,N,20251231
0002-0213_458ef2aa-cd5f-48bc-8829-82420cfed33b,0002-0213,HUMAN OTC DRUG,Humulin,R,Insulin human,"INJECTION, SOLUTION",PARENTERAL,19830627,,BLA,BLA018780,Eli Lilly and Company,INSULIN HUMAN,100,[iU]/mL,"Insulin [CS], Insulin [EPC]",,N,20241231
0002-0243_1761b768-7da0-44a9-bded-54c3bc63414a,0002-0243,HUMAN PRESCRIPTION DRUG,Zepbound,,tirzepatide,"INJECTION, SOLUTION",SUBCUTANEOUS,20231108,,NDA,NDA217806,Eli Lilly and Company,TIRZEPATIDE,5,mg/.5mL,"G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",,N,20251231
0002-0800_dec32ead-837e-4331-ab55-f3bbccea5b38,0002-0800,HUMAN OTC DRUG,Sterile Diluent,,diluent,"INJECTION, SOLUTION",SUBCUTANEOUS,19870710,,BLA,BLA018781,Eli Lilly and Company,WATER,1,mL/mL,,,N,20241231
0002-1152_b597917f-9673-4331-809d-79a538bb943c,0002-1152,HUMAN PRESCRIPTION DRUG,MOUNJARO,,tirzepatide,"INJECTION, SOLUTION",SUBCUTANEOUS,20230728,,NDA,NDA215866,Eli Lilly and Company,TIRZEPATIDE,2.5,mg/.5mL,"G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",,N,20241231
0002-1200_c2f899b5-287a-4002-ae37-f69418174eb4,0002-1200,HUMAN PRESCRIPTION DRUG,Amyvid,,Florbetapir F 18,"INJECTION, SOLUTION",INTRAVENOUS,20120601,,NDA,NDA202008,Eli Lilly and Company,FLORBETAPIR F-18,51,mCi/mL,"Positron Emitting Activity [MoA], Radioactive Diagnostic Agent [EPC]",,N,20241231
0002-1214_1761b768-7da0-44a9-bded-54c3bc63414a,0002-1214,HUMAN PRESCRIPTION DRUG,Zepbound,,tirzepatide,"INJECTION, SOLUTION",SUBCUTANEOUS,20231108,,NDA,NDA217806,Eli Lilly and Company,TIRZEPATIDE,7.5,mg/.5mL,"G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",,N,20251231
0002-1220_f615e11a-4b7c-4d64-99d2-36bc282fa391,0002-1220,HUMAN PRESCRIPTION DRUG,TAUVID,,Flortaucipir F-18,"INJECTION, SOLUTION",INTRAVENOUS,20220701,,NDA,NDA212123,Eli Lilly and Company,FLORTAUCIPIR F-18,100,mCi/mL,,,N,20251231
0002-1243_b597917f-9673-4331-809d-79a538bb943c,0002-1243,HUMAN PRESCRIPTION DRUG,MOUNJARO,,tirzepatide,"INJECTION, SOLUTION",SUBCUTANEOUS,20230728,,NDA,NDA215866,Eli Lilly and Company,TIRZEPATIDE,5,mg/.5mL,"G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",,N,20241231
0002-1340_1761b768-7da0-44a9-bded-54c3bc63414a,0002-1340,HUMAN PRESCRIPTION DRUG,Zepbound,,tirzepatide,"INJECTION, SOLUTION",SUBCUTANEOUS,20231108,,NDA,NDA217806,Eli Lilly and Company,TIRZEPATIDE,10,mg/.5mL,"G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",,N,20251231
0002-1423_1761b768-7da0-44a9-bded-54c3bc63414a,0002-1423,HUMAN PRESCRIPTION DRUG,Zepbound,,tirzepatide,"INJECTION, SOLUTION",SUBCUTANEOUS,20231108,,NDA,NDA217806,Eli Lilly and Company,TIRZEPATIDE,12.5,mg/.5mL,"G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",,N,20251231
0002-1433_d89b25b3-0f8d-4cbd-b58b-44d112cd7fe6,0002-1433,HUMAN PRESCRIPTION DRUG,Trulicity,,Dulaglutide,"INJECTION, SOLUTION",SUBCUTANEOUS,20140918,,BLA,BLA125469,Eli Lilly and Company,DULAGLUTIDE,0.75,mg/.5mL,"GLP-1 Receptor Agonist [EPC], Glucagon-Like Peptide 1 [CS], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]",,N,20241231
0002-1434_d89b25b3-0f8d-4cbd-b58b-44d112cd7fe6,0002-1434,HUMAN PRESCRIPTION DRUG,Trulicity,,Dulaglutide,"INJECTION, SOLUTION",SUBCUTANEOUS,20140918,,BLA,BLA125469,Eli Lilly and Company,DULAGLUTIDE,1.5,mg/.5mL,"GLP-1 Receptor Agonist [EPC], Glucagon-Like Peptide 1 [CS], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]",,N,20241231
0002-1436_bec46346-20b5-4dbe-bac3-b8564e906941,0002-1436,HUMAN PRESCRIPTION DRUG,EMGALITY,,galcanezumab-gnlm,"INJECTION, SOLUTION",SUBCUTANEOUS,20180927,,BLA,BLA761063,Eli Lilly and Company,GALCANEZUMAB,120,mg/mL,,,N,20241231
0002-1445_02b8e3f2-ea8d-427e-97ae-392c1245e1b0,0002-1445,HUMAN PRESCRIPTION DRUG,TALTZ,,ixekizumab,"INJECTION, SOLUTION",SUBCUTANEOUS,20160322,,BLA,BLA125521,Eli Lilly and Company,IXEKIZUMAB,80,mg/mL,"Interleukin-17A Antagonist [EPC], Interleukin-17A Antagonists [MoA]",,N,20251231
0002-1457_b597917f-9673-4331-809d-79a538bb943c,0002-1457,HUMAN PRESCRIPTION DRUG,MOUNJARO,,tirzepatide,"INJECTION, SOLUTION",SUBCUTANEOUS,20220513,,NDA,NDA215866,Eli Lilly and Company,TIRZEPATIDE,15,mg/.5mL,"G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",,N,20241231
0002-1460_b597917f-9673-4331-809d-79a538bb943c,0002-1460,HUMAN PRESCRIPTION DRUG,MOUNJARO,,tirzepatide,"INJECTION, SOLUTION",SUBCUTANEOUS,20220513,,NDA,NDA215866,Eli Lilly and Company,TIRZEPATIDE,12.5,mg/.5mL,"G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",,N,20241231
0002-1471_b597917f-9673-4331-809d-79a538bb943c,0002-1471,HUMAN PRESCRIPTION DRUG,MOUNJARO,,tirzepatide,"INJECTION, SOLUTION",SUBCUTANEOUS,20220513,,NDA,NDA215866,Eli Lilly and Company,TIRZEPATIDE,10,mg/.5mL,"G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",,N,20241231
0002-1484_b597917f-9673-4331-809d-79a538bb943c,0002-1484,HUMAN PRESCRIPTION DRUG,MOUNJARO,,tirzepatide,"INJECTION, SOLUTION",SUBCUTANEOUS,20220513,,NDA,NDA215866,Eli Lilly and Company,TIRZEPATIDE,7.5,mg/.5mL,"G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",,N,20241231
0002-1495_b597917f-9673-4331-809d-79a538bb943c,0002-1495,HUMAN PRESCRIPTION DRUG,MOUNJARO,,tirzepatide,"INJECTION, SOLUTION",SUBCUTANEOUS,20220513,,NDA,NDA215866,Eli Lilly and Company,TIRZEPATIDE,5,mg/.5mL,"G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",,N,20241231
0002-1506_b597917f-9673-4331-809d-79a538bb943c,0002-1506,HUMAN PRESCRIPTION DRUG,MOUNJARO,,tirzepatide,"INJECTION, SOLUTION",SUBCUTANEOUS,20220513,,NDA,NDA215866,Eli Lilly and Company,TIRZEPATIDE,2.5,mg/.5mL,"G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",,N,20241231
0002-2002_1761b768-7da0-44a9-bded-54c3bc63414a,0002-2002,HUMAN PRESCRIPTION DRUG,Zepbound,,tirzepatide,"INJECTION, SOLUTION",SUBCUTANEOUS,20231108,,NDA,NDA217806,Eli Lilly and Company,TIRZEPATIDE,15,mg/.5mL,"G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",,N,20251231
0002-2214_b597917f-9673-4331-809d-79a538bb943c,0002-2214,HUMAN PRESCRIPTION DRUG,MOUNJARO,,tirzepatide,"INJECTION, SOLUTION",SUBCUTANEOUS,20230728,,NDA,NDA215866,Eli Lilly and Company,TIRZEPATIDE,7.5,mg/.5mL,"G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",,N,20241231
0002-2236_d89b25b3-0f8d-4cbd-b58b-44d112cd7fe6,0002-2236,HUMAN PRESCRIPTION DRUG,Trulicity,,Dulaglutide,"INJECTION, SOLUTION",SUBCUTANEOUS,20200903,,BLA,BLA125469,Eli Lilly and Company,DULAGLUTIDE,3,mg/.5mL,"GLP-1 Receptor Agonist [EPC], Glucagon-Like Peptide 1 [CS], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]",,N,20241231
0002-2340_b597917f-9673-4331-809d-79a538bb943c,0002-2340,HUMAN PRESCRIPTION DRUG,MOUNJARO,,tirzepatide,"INJECTION, SOLUTION",SUBCUTANEOUS,20230728,,NDA,NDA215866,Eli Lilly and Company,TIRZEPATIDE,10,mg/.5mL,"G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",,N,20241231
0002-2377_bec46346-20b5-4dbe-bac3-b8564e906941,0002-2377,HUMAN PRESCRIPTION DRUG,EMGALITY,,galcanezumab-gnlm,"INJECTION, SOLUTION",SUBCUTANEOUS,20180927,,BLA,BLA761063,Eli Lilly and Company,GALCANEZUMAB,120,mg/mL,,,N,20241231
0002-2423_b597917f-9673-4331-809d-79a538bb943c,0002-2423,HUMAN PRESCRIPTION DRUG,MOUNJARO,,tirzepatide,"INJECTION, SOLUTION",SUBCUTANEOUS,20230728,,NDA,NDA215866,Eli Lilly and Company,TIRZEPATIDE,12.5,mg/.5mL,"G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",,N,20241231
0002-2457_1761b768-7da0-44a9-bded-54c3bc63414a,0002-2457,HUMAN PRESCRIPTION DRUG,ZEPBOUND,,tirzepatide,"INJECTION, SOLUTION",SUBCUTANEOUS,20231108,,NDA,NDA217806,Eli Lilly and Company,TIRZEPATIDE,15,mg/.5mL,"G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",,N,20251231
0002-2460_1761b768-7da0-44a9-bded-54c3bc63414a,0002-2460,HUMAN PRESCRIPTION DRUG,ZEPBOUND,,tirzepatide,"INJECTION, SOLUTION",SUBCUTANEOUS,20231108,,NDA,NDA217806,Eli Lilly and Company,TIRZEPATIDE,12.5,mg/.5mL,"G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",,N,20251231
0002-2471_1761b768-7da0-44a9-bded-54c3bc63414a,0002-2471,HUMAN PRESCRIPTION DRUG,ZEPBOUND,,tirzepatide,"INJECTION, SOLUTION",SUBCUTANEOUS,20231108,,NDA,NDA217806,Eli Lilly and Company,TIRZEPATIDE,10,mg/.5mL,"G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",,N,20251231
0002-2484_1761b768-7da0-44a9-bded-54c3bc63414a,0002-2484,HUMAN PRESCRIPTION DRUG,ZEPBOUND,,tirzepatide,"INJECTION, SOLUTION",SUBCUTANEOUS,20231108,,NDA,NDA217806,Eli Lilly and Company,TIRZEPATIDE,7.5,mg/.5mL,"G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",,N,20251231
0002-2495_1761b768-7da0-44a9-bded-54c3bc63414a,0002-2495,HUMAN PRESCRIPTION DRUG,ZEPBOUND,,tirzepatide,"INJECTION, SOLUTION",SUBCUTANEOUS,20231108,,NDA,NDA217806,Eli Lilly and Company,TIRZEPATIDE,5,mg/.5mL,"G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",,N,20251231
0002-2506_1761b768-7da0-44a9-bded-54c3bc63414a,0002-2506,HUMAN PRESCRIPTION DRUG,ZEPBOUND,,tirzepatide,"INJECTION, SOLUTION",SUBCUTANEOUS,20231108,,NDA,NDA217806,Eli Lilly and Company,TIRZEPATIDE,2.5,mg/.5mL,"G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",,N,20251231
0002-2980_16fba03c-8787-45b3-aa1b-1cf2b5c7610a,0002-2980,HUMAN PRESCRIPTION DRUG,RETEVMO,,selpercatinib,CAPSULE,ORAL,20200508,,NDA,NDA213246,Eli Lilly and Company,SELPERCATINIB,80,mg/1,"Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Rearranged during Transfection (RET) Inhibitors [MoA]",,N,20251231
0002-3002_b597917f-9673-4331-809d-79a538bb943c,0002-3002,HUMAN PRESCRIPTION DRUG,MOUNJARO,,tirzepatide,"INJECTION, SOLUTION",SUBCUTANEOUS,20230728,,NDA,NDA215866,Eli Lilly and Company,TIRZEPATIDE,15,mg/.5mL,"G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",,N,20241231
0002-3115_bec46346-20b5-4dbe-bac3-b8564e906941,0002-3115,HUMAN PRESCRIPTION DRUG,EMGALITY,,galcanezumab-gnlm,"INJECTION, SOLUTION",SUBCUTANEOUS,20190604,,BLA,BLA761063,Eli Lilly and Company,GALCANEZUMAB,100,mg/mL,,,N,20241231
0002-3182_d89b25b3-0f8d-4cbd-b58b-44d112cd7fe6,0002-3182,HUMAN PRESCRIPTION DRUG,Trulicity,,Dulaglutide,"INJECTION, SOLUTION",SUBCUTANEOUS,20200903,,BLA,BLA125469,Eli Lilly and Company,DULAGLUTIDE,4.5,mg/.5mL,"GLP-1 Receptor Agonist [EPC], Glucagon-Like Peptide 1 [CS], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]",,N,20241231
0002-3227_6963b20c-fce1-414e-90b6-5d0730f93191,0002-3227,HUMAN PRESCRIPTION DRUG,Strattera,,Atomoxetine hydrochloride,CAPSULE,ORAL,20021126,,NDA,NDA021411,Eli Lilly and Company,ATOMOXETINE HYDROCHLORIDE,10,mg/1,"Norepinephrine Reuptake Inhibitor [EPC], Norepinephrine Uptake Inhibitors [MoA]",,N,20241231
0002-3228_6963b20c-fce1-414e-90b6-5d0730f93191,0002-3228,HUMAN PRESCRIPTION DRUG,Strattera,,Atomoxetine hydrochloride,CAPSULE,ORAL,20021126,,NDA,NDA021411,Eli Lilly and Company,ATOMOXETINE HYDROCHLORIDE,25,mg/1,"Norepinephrine Reuptake Inhibitor [EPC], Norepinephrine Uptake Inhibitors [MoA]",,N,20241231
0002-3229_6963b20c-fce1-414e-90b6-5d0730f93191,0002-3229,HUMAN PRESCRIPTION DRUG,Strattera,,Atomoxetine hydrochloride,CAPSULE,ORAL,20021126,,NDA,NDA021411,Eli Lilly and Company,ATOMOXETINE HYDROCHLORIDE,40,mg/1,"Norepinephrine Reuptake Inhibitor [EPC], Norepinephrine Uptake Inhibitors [MoA]",,N,20241231
0002-3230_c0e0ab8a-6a1e-4361-b8c6-00163eaa0f7b,0002-3230,HUMAN PRESCRIPTION DRUG,Symbyax,,Olanzapine and Fluoxetine hydrochloride,CAPSULE,ORAL,20070409,,NDA,NDA021520,Eli Lilly and Company,FLUOXETINE HYDROCHLORIDE; OLANZAPINE,25; 3,mg/1; mg/1,"Atypical Antipsychotic [EPC], Serotonin Reuptake Inhibitor [EPC], Serotonin Uptake Inhibitors [MoA]",,N,20241231
0002-3231_c0e0ab8a-6a1e-4361-b8c6-00163eaa0f7b,0002-3231,HUMAN PRESCRIPTION DRUG,Symbyax,,Olanzapine and Fluoxetine hydrochloride,CAPSULE,ORAL,20031224,,NDA,NDA021520,Eli Lilly and Company,FLUOXETINE HYDROCHLORIDE; OLANZAPINE,25; 6,mg/1; mg/1,"Atypical Antipsychotic [EPC], Serotonin Reuptake Inhibitor [EPC], Serotonin Uptake Inhibitors [MoA]",,N,20241231
0002-3235_9b59611f-2b1b-46d7-8d7e-9d0779811309,0002-3235,HUMAN PRESCRIPTION DRUG,Cymbalta,,Duloxetine hydrochloride,"CAPSULE, DELAYED RELEASE",ORAL,20040824,,NDA,NDA021427,Eli Lilly and Company,DULOXETINE HYDROCHLORIDE,20,mg/1,"Norepinephrine Uptake Inhibitors [MoA], Serotonin Uptake Inhibitors [MoA], Serotonin and Norepinephrine Reuptake Inhibitor [EPC]",,N,20241231
0002-3238_6963b20c-fce1-414e-90b6-5d0730f93191,0002-3238,HUMAN PRESCRIPTION DRUG,Strattera,,Atomoxetine hydrochloride,CAPSULE,ORAL,20021126,,NDA,NDA021411,Eli Lilly and Company,ATOMOXETINE HYDROCHLORIDE,18,mg/1,"Norepinephrine Reuptake Inhibitor [EPC], Norepinephrine Uptake Inhibitors [MoA]",,N,20241231
0002-3239_6963b20c-fce1-414e-90b6-5d0730f93191,0002-3239,HUMAN PRESCRIPTION DRUG,Strattera,,Atomoxetine hydrochloride,CAPSULE,ORAL,20021126,,NDA,NDA021411,Eli Lilly and Company,ATOMOXETINE HYDROCHLORIDE,60,mg/1,"Norepinephrine Reuptake Inhibitor [EPC], Norepinephrine Uptake Inhibitors [MoA]",,N,20241231
0002-3240_9b59611f-2b1b-46d7-8d7e-9d0779811309,0002-3240,HUMAN PRESCRIPTION DRUG,Cymbalta,,Duloxetine hydrochloride,"CAPSULE, DELAYED RELEASE",ORAL,20040824,,NDA,NDA021427,Eli Lilly and Company,DULOXETINE HYDROCHLORIDE,30,mg/1,"Norepinephrine Uptake Inhibitors [MoA], Serotonin Uptake Inhibitors [MoA], Serotonin and Norepinephrine Reuptake Inhibitor [EPC]",,N,20241231
0002-3250_6963b20c-fce1-414e-90b6-5d0730f93191,0002-3250,HUMAN PRESCRIPTION DRUG,Strattera,,Atomoxetine hydrochloride,CAPSULE,ORAL,20050214,,NDA,NDA021411,Eli Lilly and Company,ATOMOXETINE HYDROCHLORIDE,80,mg/1,"Norepinephrine Reuptake Inhibitor [EPC], Norepinephrine Uptake Inhibitors [MoA]",,N,20241231
0002-3251_6963b20c-fce1-414e-90b6-5d0730f93191,0002-3251,HUMAN PRESCRIPTION DRUG,Strattera,,Atomoxetine hydrochloride,CAPSULE,ORAL,20050214,,NDA,NDA021411,Eli Lilly and Company,ATOMOXETINE HYDROCHLORIDE,100,mg/1,"Norepinephrine Reuptake Inhibitor [EPC], Norepinephrine Uptake Inhibitors [MoA]",,N,20241231
0002-3270_9b59611f-2b1b-46d7-8d7e-9d0779811309,0002-3270,HUMAN PRESCRIPTION DRUG,Cymbalta,,Duloxetine hydrochloride,"CAPSULE, DELAYED RELEASE",ORAL,20100115,,NDA,NDA021427,Eli Lilly and Company,DULOXETINE HYDROCHLORIDE,60,mg/1,"Norepinephrine Uptake Inhibitors [MoA], Serotonin Uptake Inhibitors [MoA], Serotonin and Norepinephrine Reuptake Inhibitor [EPC]",,N,20241231
0002-3977_16fba03c-8787-45b3-aa1b-1cf2b5c7610a,0002-3977,HUMAN PRESCRIPTION DRUG,RETEVMO,,selpercatinib,CAPSULE,ORAL,20200508,,NDA,NDA213246,Eli Lilly and Company,SELPERCATINIB,40,mg/1,"Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Rearranged during Transfection (RET) Inhibitors [MoA]",,N,20251231
0002-4112_c5ba5946-0f0a-445b-b370-6b98a6dbf6a3,0002-4112,HUMAN PRESCRIPTION DRUG,Zyprexa,,Olanzapine,TABLET,ORAL,19970623,,NDA,NDA020592,Eli Lilly and Company,OLANZAPINE,2.5,mg/1,Atypical Antipsychotic [EPC],,N,20241231
0002-4115_c5ba5946-0f0a-445b-b370-6b98a6dbf6a3,0002-4115,HUMAN PRESCRIPTION DRUG,Zyprexa,,Olanzapine,TABLET,ORAL,19961001,,NDA,NDA020592,Eli Lilly and Company,OLANZAPINE,5,mg/1,Atypical Antipsychotic [EPC],,N,20241231
0002-4116_c5ba5946-0f0a-445b-b370-6b98a6dbf6a3,0002-4116,HUMAN PRESCRIPTION DRUG,Zyprexa,,Olanzapine,TABLET,ORAL,19961001,,NDA,NDA020592,Eli Lilly and Company,OLANZAPINE,7.5,mg/1,Atypical Antipsychotic [EPC],,N,20241231
0002-4117_c5ba5946-0f0a-445b-b370-6b98a6dbf6a3,0002-4117,HUMAN PRESCRIPTION DRUG,Zyprexa,,Olanzapine,TABLET,ORAL,19961001,,NDA,NDA020592,Eli Lilly and Company,OLANZAPINE,10,mg/1,Atypical Antipsychotic [EPC],,N,20241231
0002-4182_44ded0f7-8c82-4875-ad44-db5b0354a094,0002-4182,HUMAN PRESCRIPTION DRUG,Olumiant,,baricitinib,"TABLET, FILM COATED",ORAL,20180531,,NDA,NDA207924,Eli Lilly and Company,BARICITINIB,2,mg/1,"Janus Kinase Inhibitor [EPC], Janus Kinase Inhibitors [MoA]",,N,20241231
0002-4184_736ef754-5dd5-422b-81fa-bf12e9ee8afb,0002-4184,HUMAN PRESCRIPTION DRUG,Evista,,Raloxifene hydrochloride,TABLET,ORAL,19980106,,NDA,NDA020815,Eli Lilly and Company,RALOXIFENE HYDROCHLORIDE,60,mg/1,"Estrogen Agonist/Antagonist [EPC], Selective Estrogen Receptor Modulators [MoA]",,N,20241231
0002-4312_5ef14cf2-d634-4a7b-9254-4cc480e8a48d,0002-4312,HUMAN PRESCRIPTION DRUG,Reyvow,,lasmiditan,TABLET,ORAL,20191011,,NDA,NDA211280,Eli Lilly and Company,LASMIDITAN,50,mg/1,,CV,N,20241231
0002-4415_c5ba5946-0f0a-445b-b370-6b98a6dbf6a3,0002-4415,HUMAN PRESCRIPTION DRUG,Zyprexa,,Olanzapine,TABLET,ORAL,20000110,,NDA,NDA020592,Eli Lilly and Company,OLANZAPINE,15,mg/1,Atypical Antipsychotic [EPC],,N,20241231
0002-4420_c5ba5946-0f0a-445b-b370-6b98a6dbf6a3,0002-4420,HUMAN PRESCRIPTION DRUG,Zyprexa,,Olanzapine,TABLET,ORAL,20010301,,NDA,NDA020592,Eli Lilly and Company,OLANZAPINE,20,mg/1,Atypical Antipsychotic [EPC],,N,20241231
0002-4453_c5ba5946-0f0a-445b-b370-6b98a6dbf6a3,0002-4453,HUMAN PRESCRIPTION DRUG,ZYPREXA,Zydis,Olanzapine,"TABLET, ORALLY DISINTEGRATING",ORAL,20000601,,NDA,NDA021086,Eli Lilly and Company,OLANZAPINE,5,mg/1,Atypical Antipsychotic [EPC],,N,20241231
0002-4454_c5ba5946-0f0a-445b-b370-6b98a6dbf6a3,0002-4454,HUMAN PRESCRIPTION DRUG,ZYPREXA,Zydis,Olanzapine,"TABLET, ORALLY DISINTEGRATING",ORAL,20000601,,NDA,NDA021086,Eli Lilly and Company,OLANZAPINE,10,mg/1,Atypical Antipsychotic [EPC],,N,20241231
0002-4455_c5ba5946-0f0a-445b-b370-6b98a6dbf6a3,0002-4455,HUMAN PRESCRIPTION DRUG,ZYPREXA,Zydis,Olanzapine,"TABLET, ORALLY DISINTEGRATING",ORAL,20010901,,NDA,NDA021086,Eli Lilly and Company,OLANZAPINE,15,mg/1,Atypical Antipsychotic [EPC],,N,20241231
0002-4456_c5ba5946-0f0a-445b-b370-6b98a6dbf6a3,0002-4456,HUMAN PRESCRIPTION DRUG,ZYPREXA,Zydis,Olanzapine,"TABLET, ORALLY DISINTEGRATING",ORAL,20010901,,NDA,NDA021086,Eli Lilly and Company,OLANZAPINE,20,mg/1,Atypical Antipsychotic [EPC],,N,20241231
0002-4462_21516130-0eb4-48d3-ba98-80465523793a,0002-4462,HUMAN PRESCRIPTION DRUG,Cialis,,Tadalafil,"TABLET, FILM COATED",ORAL,20031126,,NDA,NDA021368,Eli Lilly and Company,TADALAFIL,5,mg/1,"Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]",,N,20241231
0002-4463_21516130-0eb4-48d3-ba98-80465523793a,0002-4463,HUMAN PRESCRIPTION DRUG,Cialis,,Tadalafil,"TABLET, FILM COATED",ORAL,20031126,,NDA,NDA021368,Eli Lilly and Company,TADALAFIL,10,mg/1,"Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]",,N,20241231
0002-4464_21516130-0eb4-48d3-ba98-80465523793a,0002-4464,HUMAN PRESCRIPTION DRUG,Cialis,,Tadalafil,"TABLET, FILM COATED",ORAL,20031126,,NDA,NDA021368,Eli Lilly and Company,TADALAFIL,20,mg/1,"Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]",,N,20241231
0002-4465_21516130-0eb4-48d3-ba98-80465523793a,0002-4465,HUMAN PRESCRIPTION DRUG,Cialis,,Tadalafil,"TABLET, FILM COATED",ORAL,20080107,,NDA,NDA021368,Eli Lilly and Company,TADALAFIL,2.5,mg/1,"Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]",,N,20241231
0002-4479_44ded0f7-8c82-4875-ad44-db5b0354a094,0002-4479,HUMAN PRESCRIPTION DRUG,Olumiant,,baricitinib,"TABLET, FILM COATED",ORAL,20220510,,NDA,NDA207924,Eli Lilly and Company,BARICITINIB,4,mg/1,"Janus Kinase Inhibitor [EPC], Janus Kinase Inhibitors [MoA]",,N,20241231
0002-4483_1bfe414d-380c-400b-8ae2-7caa0877dcad,0002-4483,HUMAN PRESCRIPTION DRUG,Verzenio,,abemaciclib,TABLET,ORAL,20170928,,NDA,NDA208716,Eli Lilly and Company,ABEMACICLIB,50,mg/1,"Kinase Inhibitor [EPC], Kinase Inhibitors [MoA]",,N,20251231
0002-4491_5ef14cf2-d634-4a7b-9254-4cc480e8a48d,0002-4491,HUMAN PRESCRIPTION DRUG,Reyvow,,lasmiditan,TABLET,ORAL,20191011,,NDA,NDA211280,Eli Lilly and Company,LASMIDITAN,100,mg/1,,CV,N,20241231
0002-4732_44ded0f7-8c82-4875-ad44-db5b0354a094,0002-4732,HUMAN PRESCRIPTION DRUG,Olumiant,,baricitinib,"TABLET, FILM COATED",ORAL,20191008,,NDA,NDA207924,Eli Lilly and Company,BARICITINIB,1,mg/1,"Janus Kinase Inhibitor [EPC], Janus Kinase Inhibitors [MoA]",,N,20241231
0002-4815_1bfe414d-380c-400b-8ae2-7caa0877dcad,0002-4815,HUMAN PRESCRIPTION DRUG,Verzenio,,abemaciclib,TABLET,ORAL,20170928,,NDA,NDA208716,Eli Lilly and Company,ABEMACICLIB,100,mg/1,"Kinase Inhibitor [EPC], Kinase Inhibitors [MoA]",,N,20251231
0002-5337_1bfe414d-380c-400b-8ae2-7caa0877dcad,0002-5337,HUMAN PRESCRIPTION DRUG,Verzenio,,abemaciclib,TABLET,ORAL,20170928,,NDA,NDA208716,Eli Lilly and Company,ABEMACICLIB,150,mg/1,"Kinase Inhibitor [EPC], Kinase Inhibitors [MoA]",,N,20251231
0002-5340_16fba03c-8787-45b3-aa1b-1cf2b5c7610a,0002-5340,HUMAN PRESCRIPTION DRUG,RETEVMO,,selpercatinib,"TABLET, COATED",ORAL,20240410,,NDA,NDA218160,Eli Lilly and Company,SELPERCATINIB,40,mg/1,"Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Rearranged during Transfection (RET) Inhibitors [MoA]",,N,20251231
0002-5562_16fba03c-8787-45b3-aa1b-1cf2b5c7610a,0002-5562,HUMAN PRESCRIPTION DRUG,RETEVMO,,selpercatinib,"TABLET, COATED",ORAL,20240410,,NDA,NDA218160,Eli Lilly and Company,SELPERCATINIB,160,mg/1,"Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Rearranged during Transfection (RET) Inhibitors [MoA]",,N,20251231
0002-6082_16fba03c-8787-45b3-aa1b-1cf2b5c7610a,0002-6082,HUMAN PRESCRIPTION DRUG,RETEVMO,,selpercatinib,"TABLET, COATED",ORAL,20240410,,NDA,NDA218160,Eli Lilly and Company,SELPERCATINIB,80,mg/1,"Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Rearranged during Transfection (RET) Inhibitors [MoA]",,N,20251231
0002-6120_16fba03c-8787-45b3-aa1b-1cf2b5c7610a,0002-6120,HUMAN PRESCRIPTION DRUG,RETEVMO,,selpercatinib,"TABLET, COATED",ORAL,20240410,,NDA,NDA218160,Eli Lilly and Company,SELPERCATINIB,120,mg/1,"Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Rearranged during Transfection (RET) Inhibitors [MoA]",,N,20251231
0002-6145_f88837b4-7c0d-4200-aba0-e92561310058,0002-6145,HUMAN PRESCRIPTION DRUG,Baqsimi,,glucagon,POWDER,NASAL,20190724,,NDA,NDA210134,Eli Lilly and Company,GLUCAGON,3,mg/1,"Antihypoglycemic Agent [EPC], Decreased GI Motility [PE], Decreased GI Smooth Muscle Tone [PE], Decreased Glycolysis [PE], Gastrointestinal Motility Inhibitor [EPC], Increased Gluconeogenesis [PE], Increased Glycogenolysis [PE]",,N,20241231
0002-6216_1bfe414d-380c-400b-8ae2-7caa0877dcad,0002-6216,HUMAN PRESCRIPTION DRUG,Verzenio,,abemaciclib,TABLET,ORAL,20170928,,NDA,NDA208716,Eli Lilly and Company,ABEMACICLIB,200,mg/1,"Kinase Inhibitor [EPC], Kinase Inhibitors [MoA]",,N,20251231
0002-6885_14a2ffe3-1d7e-4d1b-ac44-1698d5f92da4,0002-6885,HUMAN PRESCRIPTION DRUG,Baricitinib,,baricitinib,"TABLET, FILM COATED",ORAL,20211220,,EMERGENCY USE AUTHORIZATION,,Eli Lilly and Company,BARICITINIB,4,mg/1,"Janus Kinase Inhibitor [EPC], Janus Kinase Inhibitors [MoA]",,N,20241231
0002-6902_a06ae364-e7d8-48ee-943d-a20a29045559,0002-6902,HUMAN PRESCRIPTION DRUG,JAYPIRCA,,pirtobrutinib,"TABLET, COATED",ORAL,20230127,,NDA,NDA216059,Eli Lilly and Company,PIRTOBRUTINIB,50,mg/1,"Breast Cancer Resistance Protein Inhibitors [MoA], Bruton's Tyrosine Kinase Inhibitors [MoA], Cytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], P-Glycoprotein Inhibitors [MoA]",,N,20251231
0002-7026_a06ae364-e7d8-48ee-943d-a20a29045559,0002-7026,HUMAN PRESCRIPTION DRUG,JAYPIRCA,,pirtobrutinib,"TABLET, COATED",ORAL,20230127,,NDA,NDA216059,Eli Lilly and Company,PIRTOBRUTINIB,100,mg/1,"Breast Cancer Resistance Protein Inhibitors [MoA], Bruton's Tyrosine Kinase Inhibitors [MoA], Cytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], P-Glycoprotein Inhibitors [MoA]",,N,20251231
0002-7510_e57e8ab9-295b-4fb7-b723-e7b008117e9a,0002-7510,HUMAN PRESCRIPTION DRUG,Humalog,,Insulin lispro,"INJECTION, SOLUTION",INTRAVENOUS; SUBCUTANEOUS,19960614,,BLA,BLA020563,Eli Lilly and Company,INSULIN LISPRO,100,[iU]/mL,"Insulin Analog [EPC], Insulin [Chemical/Ingredient]",,N,20241231
0002-7511_6159de02-43c9-4b4b-83be-41246382761e,0002-7511,HUMAN PRESCRIPTION DRUG,Humalog,Mix75/25,Insulin lispro,"INJECTION, SUSPENSION",SUBCUTANEOUS,19991222,,BLA,BLA021017,Eli Lilly and Company,INSULIN LISPRO,100,[iU]/mL,"Insulin Analog [EPC], Insulin [Chemical/Ingredient]",,N,20241231
0002-7516_e57e8ab9-295b-4fb7-b723-e7b008117e9a,0002-7516,HUMAN PRESCRIPTION DRUG,Humalog,,Insulin lispro,"INJECTION, SOLUTION",INTRAVENOUS; SUBCUTANEOUS,19980220,,BLA,BLA020563,Eli Lilly and Company,INSULIN LISPRO,100,[iU]/mL,"Insulin Analog [EPC], Insulin [Chemical/Ingredient]",,N,20241231
0002-7533_e57e8ab9-295b-4fb7-b723-e7b008117e9a,0002-7533,HUMAN PRESCRIPTION DRUG,Humalog,,Insulin lispro,"INJECTION, SOLUTION",INTRAVENOUS; SUBCUTANEOUS,20230802,,BLA,BLA020563,Eli Lilly and Company,INSULIN LISPRO,100,[iU]/mL,"Insulin Analog [EPC], Insulin [Chemical/Ingredient]",,N,20241231
0002-7575_dfda775c-be8e-474b-bacd-67823936663e,0002-7575,HUMAN PRESCRIPTION DRUG,Omvoh,,mirikizumab-mrkz,"INJECTION, SOLUTION",INTRAVENOUS,20231026,,BLA,BLA761279,Eli Lilly and Company,MIRIKIZUMAB,20,mg/mL,"Interleukin-23 Antagonist [EPC], Interleukin-23 Antagonists [MoA]",,N,20251231
0002-7589_33e6bc41-eab2-4967-8ebd-6174f33b1ff0,0002-7589,HUMAN PRESCRIPTION DRUG,Bebtelovimab,,Bebtelovimab,"INJECTION, SOLUTION",INTRAVENOUS,20220211,20240828,EMERGENCY USE AUTHORIZATION,,Eli Lilly and Company,BEBTELOVIMAB,87.5,mg/mL,,,N,
0002-7597_c5ba5946-0f0a-445b-b370-6b98a6dbf6a3,0002-7597,HUMAN PRESCRIPTION DRUG,ZYPREXA,Intramuscular,Olanzapine,"INJECTION, POWDER, FOR SOLUTION",INTRAMUSCULAR,20040401,,NDA,NDA021253,Eli Lilly and Company,OLANZAPINE,10,mg/2mL,Atypical Antipsychotic [EPC],,N,20241231
0002-7623_3af0bc84-13d6-46aa-a4c0-c62410b73bc6,0002-7623,HUMAN PRESCRIPTION DRUG,Alimta,,Pemetrexed disodium,"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",INTRAVENOUS,20040204,,NDA,NDA021462,Eli Lilly and Company,PEMETREXED DISODIUM HEPTAHYDRATE,500,mg/20mL,"Folate Analog Metabolic Inhibitor [EPC], Folic Acid Metabolism Inhibitors [MoA]",,N,20241231
0002-7635_41196744-bae3-4fee-86d2-2df9f7dc6a04,0002-7635,HUMAN PRESCRIPTION DRUG,ZYPREXA,Relprevv,Olanzapine pamoate,KIT,INTRAMUSCULAR,20091211,,NDA,NDA022173,Eli Lilly and Company,,,,,,N,20241231
0002-7636_41196744-bae3-4fee-86d2-2df9f7dc6a04,0002-7636,HUMAN PRESCRIPTION DRUG,ZYPREXA,Relprevv,Olanzapine pamoate,KIT,INTRAMUSCULAR,20091211,,NDA,NDA022173,Eli Lilly and Company,,,,,,N,20241231
0002-7637_41196744-bae3-4fee-86d2-2df9f7dc6a04,0002-7637,HUMAN PRESCRIPTION DRUG,ZYPREXA,Relprevv,Olanzapine pamoate,KIT,INTRAMUSCULAR,20091211,,NDA,NDA022173,Eli Lilly and Company,,,,,,N,20241231
0002-7640_3af0bc84-13d6-46aa-a4c0-c62410b73bc6,0002-7640,HUMAN PRESCRIPTION DRUG,Alimta,,Pemetrexed disodium,"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",INTRAVENOUS,20070907,,NDA,NDA021462,Eli Lilly and Company,PEMETREXED DISODIUM HEPTAHYDRATE,100,mg/4mL,"Folate Analog Metabolic Inhibitor [EPC], Folic Acid Metabolism Inhibitors [MoA]",,N,20241231
0002-7669_7ba2dde4-bb6d-4c7b-af6a-361ed01bfdf6,0002-7669,HUMAN PRESCRIPTION DRUG,CYRAMZA,,ramucirumab,SOLUTION,INTRAVENOUS,20140421,,BLA,BLA125477,Eli Lilly and Company,RAMUCIRUMAB,10,mg/mL,"VEGFR2 Inhibitors [MoA], Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]",,N,20241231
0002-7678_7ba2dde4-bb6d-4c7b-af6a-361ed01bfdf6,0002-7678,HUMAN PRESCRIPTION DRUG,CYRAMZA,,ramucirumab,SOLUTION,INTRAVENOUS,20140421,,BLA,BLA125477,Eli Lilly and Company,RAMUCIRUMAB,10,mg/mL,"VEGFR2 Inhibitors [MoA], Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]",,N,20241231
0002-7712_e57e8ab9-295b-4fb7-b723-e7b008117e9a,0002-7712,HUMAN PRESCRIPTION DRUG,Humalog,KwikPen,Insulin lispro,"INJECTION, SOLUTION",SUBCUTANEOUS,20150526,,BLA,BLA205747,Eli Lilly and Company,INSULIN LISPRO,200,[iU]/mL,"Insulin Analog [EPC], Insulin [Chemical/Ingredient]",,N,20241231
0002-7714_e57e8ab9-295b-4fb7-b723-e7b008117e9a,0002-7714,HUMAN PRESCRIPTION DRUG,Humalog,Junior KwikPen,Insulin lispro,"INJECTION, SOLUTION",SUBCUTANEOUS,20170606,,BLA,BLA020563,Eli Lilly and Company,INSULIN LISPRO,100,[iU]/mL,"Insulin Analog [EPC], Insulin [Chemical/Ingredient]",,N,20241231
0002-7715_dbb5654d-96c0-4cce-adba-5ae8c36acf80,0002-7715,HUMAN PRESCRIPTION DRUG,BASAGLAR,KwikPen,Insulin glargine,"INJECTION, SOLUTION",SUBCUTANEOUS,20151216,,BLA,BLA205692,Eli Lilly and Company,INSULIN GLARGINE,100,[iU]/mL,"Insulin Analog [EPC], Insulin [CS]",,N,20241231
